期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

糖尿病治疗药物“不良反应”的客观存在及临床对策

下载PDF
导出
摘要 1不良反应的客观存在万物都俱两面性永远是真理。药物也是如此，早期一味一味药的诞生，都是人类在尝百草中，日积月累的筛选出来的，当然一些使生物和人类致伤致死的，被称为毒药被筛选掉了；另一些起治疗作用的，就被称为药物保留下来；随着科技的发展和对疾病的深刻认识，我们目前已能从疾病的病因、发病机制等环节上，去主动寻找、加工、开发、合成治疗用药，
作者 刘赫
机构地区 北京协和医院
出处 《实用糖尿病杂志》 2013年第5期3-5,共3页 Journal of Practical Diabetology
关键词 糖尿病治疗药物 不良反应 临床 治疗作用 药物保留 发病机制 治疗用药 人类
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献23

  • 1郑郁,母义明.药品安全性监测机制讨论[J].药品评价,2012,9(1):6-8. 被引量：7
  • 2University Group Diabetes Program. A study of thd offects of hypoglycemic agents on vascular complications in patients with adult- onset diabetes Diabetes 1970 ; 19 [ Suppl2 ] :747 - 830.
  • 3Noma A. ATP-regulated , K ^+ channesis in cardiac muscle. Nature 1983 ;305:147 - 148.
  • 4Cleveland JC Jr, Heldrum DR, Cain BG, et al. Oral sulfony- lurea hypoglycemic agents prevent ischemic preconditioning in human myoeocrdium two paradoxes revisited. Circulation 1997 ;96:29 - 32.
  • 5Nissen SE, Wolski K. Effect of rosiglitazone on the risx of myocardial infarction and death from cardiorascular causes. N Engl J Med 2007 ;356:2457 -2471.
  • 6Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998;338:916 -917.
  • 7Lebovitz HF, Kreider M, Freed MI. Evaluation of liver func- tion in type2 diabetic patients during clinical trials evidence that rosigli- tazone does not cause bepatic dysfunction. Diabetes Care 2002 ; 25 : 815 -823.
  • 8Lebovitz HE. Oral therapies for diabetic hyperglycemta Endo- crinal Metab Clin North Am 2001 ;30:909 -933.
  • 9Guay DRP. Repaglinide, a novel, short-acting hypoglycemic a- gent for type 2 diabetes mellitus. Pharmacotherapy 1998 ; 18 : 1195 - 1204.
  • 10Bell PM, Hadden DR. Mefformin. Endocrinol Metab clin North Am 1997;26:523 -537.

二级参考文献17

  • 1El - Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clinical Gastroenterology and Hepatology 2006;4(3) :369 -380.
  • 2Adami HO, ChowWH, Nyren O, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Nail Cancer Inst 1996;88 (20) : 1472 - 1477.
  • 3Larsson SC, Orsini N, Brismar K, et al. Diabetes mellitus and risk of bladder cancer: a meta -analysis. Diabetologia 2006 ;49 (12) :2819 -2823.
  • 4Mitri J, Castillo J, Pittas AG. Diabetes and risk of non - Hodgkin' s lymphoma: a meta - analysis of observational studies. Diabetes Care 2008 ;31 (12) :2391 - 2397.
  • 5Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta - analysis. Diabetologia 2004; 47 (6) :1071 - 1078.
  • 6Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer 2009;16(4) :1103 - 1123.
  • 7Lipscombe LL, Goodwin PJ, Zinman B, et al. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008; 109(2) :389 -395.
  • 8Meyerhardt JA, Catalano PJ, Hailer DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. Journal of Clinical Oncology 2003,21(3) :433 -440.
  • 9Barone BB, Yeh HC, Snyder CF, et al. Long -term all - cause mortality in cancer patients with pre - existing diabetes mellitus : a systematic review and meta - analysis. JAMA 2008 ; 300 ( 23 ) : 2754 - 2764.
  • 10Zendehdel K, Nyr6n O, Ostenson CG, et al. Cancer inci- dence in patients with type 1 diabetes mellitus: a population - based cohort study in Sweden. J Natl Cancer Inst 2003 ; 95 ( 23 ) : 1797 - 1800.

共引文献30

实用糖尿病杂志
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部